Navigation Links
Roche Diabetes Care Celebrates Second Annual Infusion Site Awareness Week, Aug. 29-Sept. 4
Date:9/1/2011

INDIANAPOLIS, Sept. 1, 2011 /PRNewswire/ -- Roche Diabetes Care, makers of the ACCU-CHEK® portfolio of diabetes management products and services, is proud to host its second annual Infusion Site Awareness Week, Aug. 29-Sept. 4, a week-long effort to highlight the importance of proper infusion site management for the 400,000 people in the United States with Type 1 diabetes who use an insulin pump.

"The inaugural Infusion Site Awareness Week, which was launched during the 2010 annual American Association of Diabetes Educators (AADE) conference, helped us reach hundreds of diabetes educators and people living with Type 1 diabetes who are now better able to identify and address potential complications stemming from improper site management," said Roche Diabetes Care North America Medical Director Andreas Stuhr, M.D.

According to the Juvenile Diabetes Research Foundation (JDRF), a supporting partner for this year's campaign, as many as 3 million Americans live with type 1 diabetes, and about 15,000 children and 15,000 adults are diagnosed with the disease every year.  

"Living with type 1 diabetes requires a person to be extremely aware and knowledgeable about the disease," said Aaron Kowalski, Ph.D., Assistant Vice President of Treatment Therapies for JDRF. "In addition to monitoring blood sugar and adjusting diet and exercise, proper infusion site rotation and care is an often underemphasized, but very important part of good diabetes management. Infusion Site Awareness Week is a perfect opportunity for diabetes educators to discuss the importance of best practices for insulin pump usage with their patients, both new and old."

For people with diabetes using insulin pump therapy, the infusion site is where an insulin pump's plastic cannula or steel needle is placed under the user's skin to administer insulin. Infusion site management is the practice of choosing a site, cleaning and preparing it, properly inserting a cannula or needle, monitoring insulin flow and then regularly rotating the insertion site to avoid infection and ensure appropriate insulin delivery. In most cases, this site must be changed every one to three days and the same site must not be reused for about two weeks or until the site has fully healed.

Roche started the annual initiative last year to increase understanding and education about proper infusion site management. A 2007 study in the American Diabetes Association journal Diabetes Care reported that some adult patients experience as many as 12 issues of irritation or infection a year because of improper site maintenance. The authors concluded that "efforts to minimize the risk of irritation, scarring, and infection should include strict adherence to proper infusion site preparation, catheter insertion, and site rotation."(1)

To help increase education, Roche is distributing Infusion Site Awareness Week kits to certified diabetes educators throughout the U.S. These kits include an educational DVD explaining proper site maintenance, fact sheets to help facilitate discussions and promotional materials such as bracelets, temporary tattoos, logos and press materials to help with outreach within their communities. Information can also be found at www.infusionsitemanagement.com.

In addition to the kits, Roche is taking the conversation on infusion site management to the social web. Follow the Infusion Site Awareness movement on Twitter @infusionsite for regular updates about healthy living, diabetes management, and other important news.

"The prospect of constant finger pricks, strict diets and wearing an insulin pump all day can be devastating to newly diagnosed diabetes patients," Dr. Stuhr said. "With Infusion Site Awareness Week, we hope to make living with diabetes a little easier, a little less scary, and help people develop life-long practices that will lead to more healthy lives."

For more information, go to www.infusionsitemanagement.com.

About Roche Diabetes Care

Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 30 years, Roche has been committed to helping people with diabetes live lives that are as normal and active as possible and has been helping healthcare professionals manage their patients' condition in an optimal way. Today, the ACCU-CHEK portfolio offers people with diabetes and healthcare professionals innovative products, services and comprehensive solutions for convenient, efficient and effective diabetes management—from blood glucose monitoring through information management to insulin delivery. The ACCU-CHEK brand encompasses blood glucose meters, infusion pumps, lancing and data management systems. For more information, please visit accu-chek.com.

All trademarks used or mentioned in this release are protected by law.

For further information, please contact:
Todd A. Siesky
Public Relations Manager
Roche Diabetes Care
9115 Hague Road, Building H
Indianapolis, IN 46250-0457
Phone: +1-317-521-3966
todd.siesky@roche.com
www.accu-chek.com

(1) Phillip, Moshe, MD, Battelino, Tadej , MD, PhD, Rodriguez, Henry, Danne, Thomas, MD, and Kaufman, Francine. "Use of Insulin Pump Therapy in the Pediatric Age-Group." DiabetesCare 30.6 (2007): 1653-1662.


'/>"/>
SOURCE Roche Diabetes Care
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... From May 4 to 6, EarQ and ... opportunity to learn more about Signia’s technology and the successful business and marketing techniques ... priority to see practices succeed in this highly competitive industry,” said Ed Keller, president ...
(Date:5/6/2016)... Arizona (PRWEB) , ... May 06, 2016 , ... ... moved domains to Sleepopolis.com . , Since launching in September, 2014 Sleepopolis ... research and testing areas, which now include pillows, sheets, mattress toppers, bed frames, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... online provider of career-focused education and corporate training, and the National Military Family ... to announce Maritza Aquino as the second full-tuition scholarship recipient of 2016. ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, Inc. ... Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and Medicaid ... Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue Cross ...
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
Breaking Medicine News(10 mins):